Remnant lipoproteins induced proliferation of human prostate cancer cell, PC-3 but not LNCaP, via low density lipoprotein receptor

Cancer Epidemiology

Volumn 33, Issue 1, 2009, Pages 16-23

  Sekine, Yoshitaka ^a   Koike, Hidekazu ^a   Nakano, Takamitsu ^b   Nakajima, Katsuyuki ^b   Takahashi, Sadao ^c   Suzuki, Kazuhiro ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPAN IMMUNORESEARCH LABORATORIES   (Japan)

^c UNIVERSITY OF FUKUI   (Japan)

Author keywords

LDL; LDL receptor; Prostate cancer; Remnant lipoproteins; RLP; SREBP2

Indexed keywords

CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; SMALL INTERFERING RNA; TRIACYLGLYCEROL;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL STRAIN PC3; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLESTEROL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, LDL; RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIGLYCERIDES;

EID: 67649844035     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2009.04.004     Document Type: Article

References (31)

1. Mills P.K., Beeson W.L., Phillips R.L., and Fraser G.E. A prospective study of dietary fat and risk of prostate cancer. Cancer 64 (1989) 598-604
2. Giovannucci E.M., Rimm E.B., Colditz G.A., Stampfer M.J., Ascherio A., Chute C.C., et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85 (1993) 1571-1579
3. Havel R.J. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 5 (1994) 102-109
4. Nakajima K., Saito T., Tamura A., Suzuki M., Nakano T., Adachi M., et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-1 immunoaffinity mixed gels. Clin Chim Acta 223 (1993) 53-71
5. Takeichi S., Yukawa N., Nakajima Y., Osawa M., Saito T., Seto Y., et al. Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death. Atherosclerosis 142 (1999) 309-315
6. McNamara J.R., Shah P.K., Nakajima K., Cupples L.A., Wilson P.W., Ordovas J.M., et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 154 (2001) 229-236
7. Doi H., Kugiyama K., Ohgushi M., Sugiyama S., Matsumura T., Ohta Y., et al. Remnants of chylomircon and very low density lipoproteins impair endothelium-dependent vasorelaxation. Atherosclerosis 137 (1998) 341-349
8. Kawakami A., Tanaka A., Nakano T., Saniabadi A., and Numano F. Stimulation of arterial smooth muscle cell proliferation by remnant lipoprotein particles isolated by immuno-affinity chromatography with anti-apo A-1 and anti-apo B-100. Horm Metab Res 33 (2001) 67-72
9. Sekine Y., Koike H., Nakano T., Nakajima K., and Suzuki K. Remnant lipoproteins stimulate proliferation and activate MAPK and Akt signaling pathways via G protein-coupled receptor in PC-3 prostate cancer cells. Clin Chim Acta 383 (2007) 78-84
10. Takahashi S., Sakai J., Fujino T., Miyamori I., and Yamamoto T.T. The very low density lipoprotein receptor-a peripheral lipoprotein receptor for remnant lipoproteins into fatty acid active tissues. Mol Cell Biochem 248 (2003) 121-127
11. Chen Y., and Hughes-Fulford M. Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2. Int J Cancer 91 (2001) 41-45
12. Takahashi S., Kawarabayasi Y., Nakai T., Sakai J., and Yamamoto T. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA 89 (1992) 9252-9256
13. Sakai J., Hoshino A., Takahaishi S., Miura Y., Ishii H., Suzuki H., et al. Structure, chromosome location, and expression of the human very low density lipoprotein receptor gene. J Biol Chem 269 (1994) 2173-2182
14. Tam S.-P., Brissette L., Ramharack R., and Deeley R.G. Differences between the regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor in human hepatoma cells and fibroblasts reside primarily at the translational and post-translational levels. J Biol Chem 266 (1991) 16764-16773
15. Lum D.F., McQuaid K.R., Gilbertson V.L., and Hughes-Fulford M. Coordinate up-regulation of low-density lipoprotein receptor and cyclooxygenase-2 gene expression in human colorectal cells and in colorectal adenocarcinoma biopsies. Int J Cancer 83 (1999) 162-166
16. Wuermli L., Joerger M., Henz S., Schmid H.P., Riesen W.F., Thomas G., et al. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 8 (2005) 316-320
17. Kosaka S., Takahashi S., Masamura K., Kanehara H., Sakai J., Tohda G., et al. Evidence of macrophage foam cell formation by very low density lipoprotein receptor. Circulation 103 (2001) 1142-1147
18. Suzuki K., Nakazato H., Matsui H., Ono Y., Nakazato H., Koike H., et al. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer. J Leukoc Biol 69 (2001) 531-537
19. Suzuki K., Matsui M., Hasumi M., Ono Y., Nakazato H., Koike H., et al. Expression profiles in human BPH: utilization of laser-capture microdissection and quantitative real-time PCR. Anticancer Res 21 (2001) 3861-3864
20. Suzuki K., Koike H., Matsui H., Ono Y., Hasumi M., Nakazato H., et al. Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3. Int J Cancer 99 (2002) 846-852
21. Horton J.D., and Shimomuraa I. Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. Curr Opin Lipidol 10 (1999) 143-150
22. Sheng Z., Otani H., Brown M.S., and Goldstein J.L. Independent regulation of sterol regulatory element binding proteins 1 and 2 in hamster liver. Proc Natl Acad Sci USA 92 (1995) 935-938
23. Campos E., Nakajima K., Tanaka A., and Harvel R.J. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res 33 (1992) 369-380
24. Shin H.K., Kim Y.K., Kim K.Y., Lee J.H., and Hong K.W. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation. Circulation 109 (2004) 1022-1028
25. Chen T., Wu F., Chen F.M., Tian J., and Qu S. Variations of very low-density lipoprotein receptor subtype expression in gastrointestinal adenocarcinoma cells with various differentiations. World J Gastroenterol 11 (2005) 2817-2821
26. Briggs M.R., Yokoyama C., Wang, Brown M.S., and Goldstein J.L. Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. J Biol Chem 268 (1993) 14490-14496
27. Sheng Z., Otani H., Brown M.S., and Goldstein L.L. Independent regulation of sterol regulatory element binding proteins 1 and 2 in hamster liver. Proc Natl Acad Sci USA 92 (1995) 935-938
28. Heemers H., Maes B., Foufelle F., Heyns W., Verhoeven G., and Johannes V.S. Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol Endocrinol 15 (2001) 1817-1828
29. Susan L.E., Richard S., Tanis G.W., Majid A., Dawn R.B., Martin E.G., et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 64 (2004) 2212-2221
30. Jennifer Y., Judi M., Marc B.G., Gajanan B., and Glenn J.B. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 176 (2006) 520-525
31. Usui S., Suzuki K., Yamanaka H., Yamanaka H., Nakano T., Nakajima K., et al. Estrogen treatment of prostate cancer increases triglycerides in lipoproteins as demonstrated by HPLC and immunoseparation techniques. Clin Chim Acta 317 (2002) 133-143